Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia

Published:2016-07-26 Issue:5 Volume:104 Page:605-611
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Hino Akihisa,Yoshida Hitoshi,Tada Yuma,Koike Midori,Minami Ryota,Masaie Hiroaki,Ishikawa Jun

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-016-2071-6.pdf

Reference28 articles.

1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, IRIS Investigators, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.

2. Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, et al. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol. 2004;80(3):261–6.

3. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29(5):1123–32.

4. Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Anticancer Res. 2015;35(12):6355–64.

5. Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;. doi: 10.1038/leu.2016.104 .

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa;eJHaem;2024-07-31

2. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia;Hemato;2023-07-14

4. Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin–aldosterone–angiotensin system inhibitors in patients with chronic myelogenous leukemia;International Journal of Hematology;2022-08-06

5. Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients;Nephrology;2022-01-06